AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18447762
Drug: Active intervention
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intervention by drug consultation center (DCC) - information by phone, mailed written form, and text messages
Trial: 16487434
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg p.o. daily at bedtime)
Trial: 9361332
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg haloperidol (i.v.)
Trial: 9361332
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg haloperidol (i.v.)
Trial: 22205309
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (RW) with 30 g alcohol/d
Trial: 22205309
Drug: Gin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gin with 30 g alcohol/d
Trial: 18176337
Drug: Dexmethylphenidate extended-release
RxNorm normalized name: dexmethylphenidate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmethylphenidate extended-release (D-MPH-ER) 20 mg/day
Trial: 7564470
Drug: Busulfan plus
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan plus continuous oral vitamin A
Trial: 1948817
Drug: Protamine chloride
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine chloride 80 mg
Trial: 1948817
Drug: Protamine chloride
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine chloride 100 mg
Trial: 1948817
Drug: Protamine chloride
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine chloride 20-100 mg
Trial: 1948817
Drug: Protamine chloride
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine chloride 60-100 mg
Trial: 6119712
Drug: Neuroleptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic therapy with constant doses of butyrophenones
Trial: 27636018
Drug: Kisspeptin-10 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kisspeptin-10 (4 μg/kg/h) infusion
Trial: 27636018
Drug: NK3R antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK3R antagonist AZD4901 40 mg twice daily orally
Trial: 27636018
Drug: NK3R antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK3R antagonist AZD4901
Trial: 22307881
Drug: Veterans Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans Health Administration Vocational Rehabilitation Program (VRP)
Trial: 17940786
Drug: Submucosal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal infiltration with 2 mg/kg tramadol in 3 ml of normal saline (1.5 ml per tonsil)
Trial: 15965309
Drug: Entacapone 200
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg administered 4 times during the day with controlled-release levodopa/carbidopa 100 mg/25 mg (Sinemet CR)
Trial: 12798612
Drug: MDCK cell
RxNorm normalized name: influenza virus vac qv 22-23 (6 mos up) MDCK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCK cell grown influenza vaccine
Trial: 12798612
Drug: Egg-derived influenza
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-derived influenza vaccine
Trial: 10822319
Drug: Perindopril 4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4-8 mg/daily
Trial: 1513922
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 to 3.5 mg/day)
Trial: 6381081
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (postural drainage and periodic application of a face mask with positive expiratory pressure)
Trial: 6381081
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (PEP in the sitting position)
Trial: 6381081
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (postural drainage, percussion and vibration)
Trial: 6381081
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment D (forced expiration technique in the sitting position)
Trial: 27049053
Drug: Trial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial preparation (2 × 250 mg)
Trial: 27049053
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (2 × 250 mg)
Trial: 27049053
Drug: Trial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial preparation and Reference preparation
Trial: 23091148
Drug: AL (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL (25 mg of allopurinol/kg of body mass)
Trial: 23091148
Drug: UAF (AL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UAF (AL plus 6.25 g of UA sodium salt/kg of feed)
Trial: 23091148
Drug: UAI (AL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UAI (AL plus 120 mg of UA sodium salt injected daily)
Trial: 23091148
Drug: INOAL (INO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INOAL (INO plus 50 mg of allopurinol/kg of body mass)
Trial: 19605567
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of sucrose (37.5 g) 2 h after breakfast and lunch
Trial: 19605567
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of sucrose (75 g, equivalent to 2 cans of a soft drink)
Trial: 8931684
Drug: Dolasetron mesylate
RxNorm normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate 0.6 mg/kg
Trial: 1563056
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (2 ml, 8 mg)
Trial: 1563056
Drug: Hyperbaric tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric tetracaine (2 ml, 8 mg)
Trial: 3910157
Drug: High-dose fractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fractionated pre-operative irradiation (25.5 Gy in 5-7 days)
Trial: 10847307
Drug: Other antipsychotic
RxNorm normalized name: Other antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antipsychotic drugs (Control)
Trial: 8838441
Drug: 311C90 (1-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 311C90 (1-50 mg, single oral doses)
Trial: 1289588
Drug: Cefprozil (CFPZ)
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil (CFPZ) at a mean dose of 8.4 mg/kg, administered 3-4 times daily for an average of 6 days.
Trial: 1289588
Drug: Cefprozil (CFPZ)
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil (CFPZ) at a daily dose of 30.1-45.0 mg/kg.
Trial: 1289588
Drug: Cefprozil (CFPZ)
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil (CFPZ) compared to other antibiotics (CEX, CCL, ABPC, DMPPC, MCIPC).
Trial: 3885985
Drug: Bepridil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (400 mg/day for 10 weeks)
Trial: 20121112
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 1)
Trial: 20121112
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 2)
Trial: 20121112
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m² and cetuximab with extended field radiation therapy (EFRT) (DL 1)
Trial: 20473913
Drug: Catumaxomab (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catumaxomab (10, 20, 50 and 150 mug i.p. infusion on Days 0, 3, 7 and 10)
Trial: 3792435
Drug: Aspirin 5
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 5 mg/kg
Trial: 3792435
Drug: Aspirin 10
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10 mg/kg
Trial: 12365879
Drug: Specific preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific preventive intervention (low-dose risperidone therapy, mean dosage 1.3 mg/d, and cognitive behavior therapy)
Trial: 29938452
Drug: UI05MSP015CT (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UI05MSP015CT (15 mg once a day)
Trial: 29938452
Drug: Mosapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride (5 mg three times a day, control group)
Trial: 26360545
Drug: Computerized Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Cognitive Behavioral Therapy (CCBT)
Trial: 24577019
Drug: IV dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dexmedetomidine (0.2 μg/kg/h titrated to 0.7 μg/kg/h)
Trial: 10362386
Drug: Flurbiprofen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (40 mg, two patches) administered 12 hours before exercise
Trial: 10362386
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches administered 12 hours before exercise
Trial: 28531791
Drug: Brioche group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brioche group (65 g brioche enriched in protein and energy, 12.8 g protein, 180 kcal)
Trial: 28531791
Drug: Supplement group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement group (200-ml energy-dense liquid, 14 g protein, 200 kcal)
Trial: 22464973
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 mg once-daily
Trial: 22464973
Drug: JNJ-37822681 10
RxNorm normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-37822681 10 mg bid vs Olanzapine
Trial: 11014413
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and caffeine
Trial: 17628221
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and placebo
Trial: 10942231
Drug: ATRA followed
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA followed by three courses of daunorubicin-AraC chemotherapy
Trial: 1603224
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (9 g a day)
Trial: 6141858
Drug: Almitrine 100
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 100 mg orally
Trial: 26898748
Drug: Intensive Behavior
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Behavior Therapy fee-for-service (FFS) model
Trial: 18622251
Drug: Lisinopril-based regimen
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril-based regimen (n = 13)
Trial: 15913920
Drug: Desipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (up to 300 mg per day)
Trial: 1095122
Drug: Nafoxidine (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafoxidine (reference compound)
Trial: 22846643
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose acupuncture (additional 4 needles at non‐acupoints bilaterally)
Trial: 22846643
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose acupuncture (one needle at point Hegu bilaterally)
Trial: 22846643
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose acupuncture
Trial: 22846643
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose acupuncture
Trial: 9698663
Drug: Parenteral polyoestradiol
RxNorm normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral polyoestradiol phosphate (PEP) 240 mg/month (group 2, n = 227)
Trial: 7137990
Drug: Aerosolized rimantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized rimantadine HCl 25 mg in saline (10 min exposure twice daily)
Trial: 7137990
Drug: Oral rimantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rimantadine HCl 50 mg (every 6 h, three times daily)
Trial: 7137990
Drug: Placebo (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (both aerosol and oral routes)
Trial: 7137990
Drug: Aerosolized rimantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized rimantadine and oral rimantadine
Trial: 28299764
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of furosemide (120 mg stat)
Trial: 28299764
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of furosemide (4 mg/minute)
Trial: 28299764
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection and infusion of furosemide
Trial: 27219099
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) administered before viewing images (encoding condition)
Trial: 27219099
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) administered immediately after viewing images (consolidation condition)
Trial: 27219099
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered both before and after viewing images (control condition)
Trial: 27219099
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg) in encoding condition with greater alcohol-induced stimulation
Trial: 23723317
Drug: Rituximab retreatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab retreatment at 1000 mg×1 (Arm A)
Trial: 23723317
Drug: Rituximab retreatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab retreatment at 1000 mg×2 (Arm B)
Trial: 15650985
Drug: Oxycodone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.5 mg/kg/h
Trial: 15650985
Drug: Oxycodone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 1.0 mg/kg/h
Trial: 15650985
Drug: Oxycodone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.5 mg/kg/h and 1.0 mg/kg/h
Trial: 11205921
Drug: TCR-zeta molecule
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCR-zeta molecule expression
Trial: 2648188
Drug: 1.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g/kg protein diet
Trial: 2648188
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg diet with protein evenly distributed between meals
Trial: 2648188
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg diet with protein restricted to the evening meal
Trial: 30794334
Drug: Budesonide with
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide with probiotic supplements (BP)
Trial: 29029260
Drug: RSV postfusion
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV postfusion F protein vaccine (120 µg) with glucopyranosyl lipid adjuvant (5 µg)
Trial: 29029260
Drug: RSV postfusion
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV postfusion F protein vaccine
Trial: 25599284
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg plus optimized background regimen (OBR)
Trial: 23568514
Drug: Standardized hypnotherapeutic‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized hypnotherapeutic‐behavioral treatment (n = 20)
Trial: 15339772
Drug: Misoprostol (25-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (25-microg intravaginal dose)
Trial: 10513186
Drug: LA with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA with 2 ml of 1% lidocaine using a 24‐gauge needle
Trial: 10513186
Drug: LA with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA with 0.5 ml of 1% lidocaine using a 27‐gauge needle
Trial: 8655712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nested PCR and immunohistochemistry
Trial: 1517929
Drug: Prednisone therapy
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone therapy for 12 weeks
Trial: 1517929
Drug: Placebo dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosing for 12 weeks
Trial: 6391140
Drug: Thymosin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin treatment
Trial: 27256936
Drug: Drug Adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Adherence Enhancement Program
Trial: 22031518
Drug: Standard glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose control through insulin sliding scale treatment
Trial: 15733643
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment expectancy
Trial: 15733643
Drug: Taking pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking pain medication and poor functional status at baseline
Trial: 12660386
Drug: High-strength levorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-strength levorphanol (0.75 mg)
Trial: 12660386
Drug: Low-strength levorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-strength levorphanol (0.15 mg)
Trial: 10713745
Drug: Serum insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum insulin concentration before eating the test meal
Trial: 8661977
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin (sCT) (all doses)
Trial: 1997698
Drug: Oral BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCG
Trial: 6581174
Drug: Tetracycline therapy
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline therapy (daily for 50 weeks)
Trial: 28575910
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of colostrum (OAC)
Trial: 22880805
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cefazolin sodium intravenously 1 h prior to catheter insertion
Trial: 18978105
Drug: 10-microgram E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-microgram E2 vaginal tablets
Trial: 16085584
Drug: (99m)Tc‐tetrofosmin uptake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc‐tetrofosmin uptake after nitrate administration
Trial: 16085584
Drug: (99m)Tc‐tetrofosmin perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc‐tetrofosmin perfusion defect severity after nitrate administration
Trial: 11910262
Drug: Paroxetine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine at 20 mg/day for 10 days
Trial: 11910262
Drug: Sertraline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline at 50 mg/day for 3 days, followed by 100 mg/day for 10 days
Trial: 11910262
Drug: Fluoxetine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine at 20 mg/day for 28 days
Trial: 3529911
Drug: Flecainide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (up to 2 mg/kg intravenously and then orally)
Trial: 3529911
Drug: Quinidine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (up to 1.2 g orally)
Trial: 26664304
Drug: Atorvastatin 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 160 mg loading dose followed by 80 mg daily
Trial: 19903982
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg, 1 week)